| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
2-Thiocytidine targets DNA synthesis in cancer cells. As a purine nucleoside analog, it is incorporated into DNA during replication, leading to chain termination and inhibition of DNA synthesis. This disruption of DNA replication triggers apoptosis in susceptible cancer cells. The compound's sulfur substitution at the C2 position may enhance its activity and selectivity.
|
|---|---|
| ln Vitro |
2-Thiocytidine demonstrates potent in vitro antitumor activity against indolent lymphoid malignancies. It inhibits DNA synthesis and induces apoptosis in cancer cells. The compound's activity is typically assessed in cell viability assays using cancer cell lines, where it exhibits concentration-dependent inhibition of proliferation.
|
| ln Vivo |
In vivo activity of 2-thiocytidine has not been extensively documented. Its potent in vitro antitumor activity against lymphoid malignancies suggests potential for in vivo efficacy in animal models of cancer. Further in vivo studies are needed to evaluate its pharmacokinetic properties, antitumor efficacy, and safety profile.
|
| Enzyme Assay |
In vitro enzyme assays for 2-thiocytidine are not typically performed, as the compound's mechanism involves incorporation into DNA rather than enzyme inhibition. Its effects on DNA synthesis can be assessed by measuring the incorporation of radiolabeled nucleotides into DNA in treated cells.
|
| Cell Assay |
In vitro cellular assays for 2-thiocytidine involve treating cancer cell lines with varying concentrations of the compound and measuring cell viability using MTT or other assays. DNA synthesis inhibition is assessed by measuring the incorporation of radiolabeled thymidine or by flow cytometry-based cell cycle analysis. Apoptosis is evaluated by Annexin V staining or caspase activity assays.
|
| Animal Protocol |
In vivo animal experiments for 2-thiocytidine are not extensively documented. If used in animal models of cancer, typical protocols would involve administering the compound to tumor-bearing mice and evaluating efficacy by measuring tumor growth inhibition and survival rates.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 2-thiocytidine are limited. The compound has a molecular weight of 259.28 and a molecular formula of C9H13N3O4S. Its absorption, distribution, metabolism, and excretion properties have not been characterized.
|
| Toxicity/Toxicokinetics |
Toxicological data for 2-thiocytidine are limited. As a nucleoside analog, it may have potential for toxicity at higher concentrations. The compound is intended for research use only. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
2-Thiocytidine is a type of cytidine compound.
2-Thiocytidine (CAS#: 13239-97-9) has the molecular formula C9H13N3O4S and a molecular weight of 259.28. It is a thionucleoside analog with broad antitumor activity targeting indolent lymphoid malignancies. The compound inhibits DNA synthesis and induces apoptosis. It is for research use only. |
| Molecular Formula |
C9H13N3O4S
|
|---|---|
| Molecular Weight |
259.28
|
| Exact Mass |
259.062
|
| CAS # |
13239-97-9
|
| PubChem CID |
3011746
|
| Appearance |
White to off-white solid powder
|
| Density |
1.9±0.1 g/cm3
|
| Boiling Point |
540.5±60.0 °C at 760 mmHg
|
| Melting Point |
208-209 °C (lit.)
|
| Flash Point |
280.7±32.9 °C
|
| Vapour Pressure |
0.0±3.3 mmHg at 25°C
|
| Index of Refraction |
1.788
|
| LogP |
-1.33
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
17
|
| Complexity |
386
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=CN(C(=S)N=C1N)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O
|
| InChi Key |
RHFUOMFWUGWKKO-XVFCMESISA-N
|
| InChi Code |
InChI=1S/C9H13N3O4S/c10-5-1-2-12(9(17)11-5)8-7(15)6(14)4(3-13)16-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,17)/t4-,6-,7-,8-/m1/s1
|
| Chemical Name |
4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2-thione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 125 mg/mL (482.10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8568 mL | 19.2842 mL | 38.5683 mL | |
| 5 mM | 0.7714 mL | 3.8568 mL | 7.7137 mL | |
| 10 mM | 0.3857 mL | 1.9284 mL | 3.8568 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
